NHP Hidradenitis Suppurativa (HS) Model

Hidradenitis suppurativa (HS) is a chronic, painful and disfiguring inflammatory skin disease affecting the apocrine gland areas (axillae, inguinal area, buttocks, chest). Its pathogenesis involves complex immune dysregulation, including innate immune responses (macrophages, neutrophils, IL-1β, TNF-α), Th1/Th17 cellular immunity, and B cell involvement. HKeyBio provides a well-characterized NHP HS model that recapitulates key features of human HS, including dermal tunnels, neutrophil infiltration, and upregulation of HS-related inflammatory genes. This model provides a powerful platform for preclinical efficacy testing of novel HS therapies.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Main features and benefits

Clinically relevant – Mimics human HS: dermal tunnels, neutrophil infiltration, chronic inflammatory skin lesions.

Multi-mechanism involved – recapitulates innate (IL-1β, TNF-α, neutrophils) and adaptive (Th1/Th17, B cells) immune components.

Comprehensive endpoint - clinical observation, histopathology, and mRNA expression of HS-related genes (IL-1β, TNF-α, CXCL1, CXCL8, Th17 markers).

Translational Value – Ideal for testing biologics (anti-TNF, anti-IL-1, anti-IL-17), JAK inhibitors, and small molecules.

IND Ready Packet – Research can be conducted in accordance with GLP principles.

Technical data and verification

Representative data for our NHP HS model:

NHP hidradenitis suppurativa model

Application areas

• Efficacy testing of biologics (anti-TNF, anti-IL-1, anti-IL-17/23), JAK inhibitors, and small molecule anti-inflammatory drugs

• Target validation of innate pathways and Th1/Th17 pathways in HS

• Biomarker discovery (gene signatures, soluble mediators)

• Mechanism of action (MOA) studies

• Toxicology and safety pharmacology studies to support IND

Model specifications

scope	Specification
Species	cynomolgus monkey ( Macaca fascicularis )
induction method	Proprietary multi-step protocol (combination of mechanical/chemical/immunostimulation) – details available in CDA
study time	6–10 weeks (induction + treatment phase)
critical endpoint	Clinical score (erythema, nodules, tunnels), histopathology (dermal tunnels, inflammatory infiltrates), mRNA expression of IL-1β, TNF-α, CXCL1, CXCL8, Th17 markers, immunohistochemistry
packet	Raw data, analysis reports, histological sections, gene expression data, bioinformatics (optional)

❓ FAQ

Q: What is unique about this NHP HS model?

A: It outlines the complex immune landscape of human HS, including innate (neutrophils, macrophages) and adaptive (Th1/Th17, B cells) components, as well as the formation of dermal tunnels and upregulation of key inflammatory mediators.

Q: Can this model be used for IND support studies?

Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).

Q: Do you offer customized research plans?

Answer: Of course. Our scientific team tailors induction protocols, treatment plans and endpoint analyzes for your specific drug candidate.

Q: What are the typical readings used to evaluate treatment effectiveness?

A: Clinical scoring of skin lesions, histopathological assessment of dermal channels and inflammatory infiltrates, and qPCR of HS-related gene expression (IL-1β, TNF-α, CXCL1, CXCL8, Th17 markers).